Dose escalation study of ARN-509 with everolimus in patients with progressive metastatic castration-resistant prostate cancer.

Trial Profile

Dose escalation study of ARN-509 with everolimus in patients with progressive metastatic castration-resistant prostate cancer.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jul 2014

At a glance

  • Drugs Apalutamide (Primary) ; Everolimus
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 23 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top